Malarial Host-Parasite Clash Causes Deadly Blood Sugar Drop

Scientists say they have finally figured out why some people with severe malaria end up with dangerous hypoglycemia, also reporting that the condition starves the parasite into changing tactics from virulence to transmission.

Written byNatalia Mesa, PhD
| 4 min read
Pink and purple <em>Plasmodium</em> parasites inside red blood cells
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Malaria is one of the world's deadliest diseases, responsible for 627,000 deaths worldwide in 2020 alone. In severe cases, patients develop dangerously low blood sugar levels. This complication is especially perilous in children and can be fatal if left untreated, but why it develops in the first place has been a long-standing mystery.

Now, in a study published Friday (July 15) in Cell Metabolism, researchers describe the complicated tug-of-war between host and parasite that appears to explain malaria-associated hypoglycemia. According to the study, the host’s blood sugar drops to dangerously low levels as the malaria parasite destroys blood cells. This starves the parasite, which responds by becoming less likely to kill the already-fragile host—but more likely to spread to others.

The researchers explain that both the host and the parasite are demonstrating adaptive behaviors during this process. The host is ridding itself of the parasite by lowering its blood sugar, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • A black and white headshot

    As she was completing her graduate thesis on the neuroscience of vision, Natalia found that she loved to talk to other people about how science impacts them. This passion led Natalia to take up writing and science communication, and she has contributed to outlets including Scientific American and the Broad Institute. Natalia completed her PhD in neuroscience at the University of Washington and graduated from Cornell University with a bachelor’s degree in biological sciences. She was previously an intern at The Scientist, and currently freelances from her home in Seattle. 

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies